BJL
ALLO icon

Brighton Jones LLC’s Allogene Therapeutics ALLO Stock Holding History

Brighton Jones LLC’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.1K Buy
+34,452
New +$69.1K ﹤0.01% 1138
2025
Q4 		– Sell
-25,168
Closed -$31.2K – 90
2025
Q3 		$31.2K Buy
25,168
+11,311
+82% +$13.5K ﹤0.01% 1015
2025
Q2 		$15.7K Buy
13,857
+945
+7% +$1.26K ﹤0.01% 921
2025
Q1 		$18.9K Buy
+12,912
New +$24.3K ﹤0.01% 695

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brighton Jones LLC's ALLO Position: Q1 2026 in Review

Brighton Jones LLC opened a new position in Allogene Therapeutics (ALLO) in Q1 2026: 34,452 shares worth $84.1K. The stake represents ﹤0.01% of the portfolio and ranks #1138 among its holdings. This is a return to the name: Brighton Jones LLC previously reported a position in ALLO as recently as Q3 2025.

Brighton Jones LLC first reported a position in ALLO in Q1 2025 and has held it in 4 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Brighton Jones LLC held 34,452 shares of Allogene Therapeutics worth $84.1K as of Q1 2026.
  • Allogene Therapeutics was a new Brighton Jones LLC position in Q1 2026.
  • Allogene Therapeutics made up ﹤0.01% of Brighton Jones LLC's portfolio in Q1 2026, its #1138 holding.
  • Brighton Jones LLC first reported a position in Allogene Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Brighton Jones LLC's 13F filing for Q1 2026, filed 28 Apr 2026.